First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Accelerating sustainability in Indian pharma industry
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Subscribe To Our Newsletter & Stay Updated
